Repurposing the repurposed: thalidomide analogs as immune stimulants to overcome T cell exhaustion

Chamberlain, 2014, Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nat. Struct. Mol. Biol., 21, 803, 10.1038/nsmb.2874 Fink, 2018, Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice, Blood, 132, 1535, 10.1182/blood-2018-05-852798 Gandhi, 2014, Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4CRBN, Br. J. Haematol., 164, 811, 10.1111/bjh.12708 Geng, 2022, Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling, Cell Chemical Biology, 29, 1260, 10.1016/j.chembiol.2022.05.012 Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 355, 1428, 10.1126/science.aaf1292 Jan, 2021, Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide, Nat. Rev. Clin. Oncol., 18, 401, 10.1038/s41571-021-00479-z Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent, Science, 355, 1423, 10.1126/science.aaf0683 Kronke, 2015, Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS, Nature, 523, 183, 10.1038/nature14610 Kronke, 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, 343, 301, 10.1126/science.1244851 Lu, 2014, The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins, Science, 343, 305, 10.1126/science.1244917 Wu, 2022, Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1, Blood, 139, 2024, 10.1182/blood.2021014701